FourThought Financial Partners LLC Buys 3,555 Shares of AstraZeneca PLC $AZN

FourThought Financial Partners LLC increased its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 2.5% in the third quarter, Holdings Channel.com reports. The firm owned 147,010 shares of the company’s stock after buying an additional 3,555 shares during the quarter. FourThought Financial Partners LLC’s holdings in AstraZeneca were worth $11,279,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in AZN. Rakuten Investment Management Inc. bought a new stake in shares of AstraZeneca during the third quarter worth $31,000. E Fund Management Hong Kong Co. Ltd. lifted its stake in shares of AstraZeneca by 144.0% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 466 shares of the company’s stock valued at $36,000 after acquiring an additional 275 shares during the last quarter. VSM Wealth Advisory LLC acquired a new stake in shares of AstraZeneca during the 2nd quarter valued at $33,000. FSA Wealth Management LLC grew its position in AstraZeneca by 376.0% during the 2nd quarter. FSA Wealth Management LLC now owns 476 shares of the company’s stock worth $33,000 after acquiring an additional 376 shares during the last quarter. Finally, Abound Wealth Management increased its holdings in AstraZeneca by 1,767.9% in the 3rd quarter. Abound Wealth Management now owns 523 shares of the company’s stock worth $40,000 after purchasing an additional 495 shares in the last quarter. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Trading Up 0.4%

AZN opened at $195.00 on Tuesday. AstraZeneca PLC has a twelve month low of $122.48 and a twelve month high of $212.71. The company has a fifty day moving average of $148.76 and a 200-day moving average of $107.42. The stock has a market cap of $302.42 billion, a PE ratio of 64.78, a price-to-earnings-growth ratio of 1.59 and a beta of 0.32. The company has a quick ratio of 0.69, a current ratio of 0.88 and a debt-to-equity ratio of 0.54.

AstraZeneca Announces Dividend

The firm also recently disclosed a dividend, which will be paid on Monday, March 23rd. Stockholders of record on Friday, February 20th will be paid a $1.595 dividend. This represents a dividend yield of 156.0%. The ex-dividend date of this dividend is Friday, February 20th. AstraZeneca’s payout ratio is currently 66.26%.

Analysts Set New Price Targets

AZN has been the topic of a number of recent research reports. HSBC reissued a “buy” rating and set a $108.00 price target on shares of AstraZeneca in a research note on Wednesday, December 10th. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of AstraZeneca in a research report on Friday, February 6th. TD Cowen reiterated a “buy” rating on shares of AstraZeneca in a report on Tuesday, December 9th. Guggenheim restated a “buy” rating on shares of AstraZeneca in a report on Wednesday, December 3rd. Finally, Wall Street Zen downgraded AstraZeneca from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 17th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $95.75.

AstraZeneca Profile

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.